<DOC>
	<DOCNO>NCT00002363</DOCNO>
	<brief_summary>To assess effect two dos synthetic peptide construction 3 ( SPC3 ) HIV-1 plasma level ( measure RNA PCR Amplicor ) lymphocyte subset patient initial viral load 10,000 copies/ml . To study safety SPC3 kinetics HIV-1 plasma level change .</brief_summary>
	<brief_title>The Safety Effectiveness SPC3 HIV-1 Infected Patients</brief_title>
	<detailed_description>The first five patient receive SPC3 daily 3 week . If dose tolerate , dose increase give next 5 patient 3 week . The remain ten patient receive dose SPC3 base response previous two dose level . Patients follow day 28 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Antiretrovirals provide regimen stable least 6 week prior study screen . Patients must : HIV seropositivity least 6 month . CD4 &gt; = 100 cells/mm3 . HIV RNA PCR ( Amplicor ) &gt; 10,000 copies/ml . No significant active opportunistic infection tumor study entry . FDA DISCLAIMER : The FDA encourage inclusion female childbearing potential study protocol , sponsor protocol specifically exclude female childbearing potential study include female sterile . Any question inclusion/exclusion criterion direct study 's contact person . Prior Medication : Allowed : Prior antiretrovirals . Exclusion Criteria Coexisting Condition : Patients follow condition exclude : Inability communicate investigator deem likely noncompliant study . Concurrent Medication : Excluded : Any drug may interact SPC3 ( e.g. , suramin ) . Patients follow prior condition exclude : History relevant drug hypersensitivity . Prior Medication : Excluded : Investigational drug within past 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 1999</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>